Mostrar registro simples

dc.contributor.authorGrangeiro, Alexandrept_BR
dc.contributor.authorSantos, Lorruan Alves dopt_BR
dc.contributor.authorEstevam, Denize Lotufopt_BR
dc.contributor.authorMunhoz, Rosemeirept_BR
dc.contributor.authorArruda, Érico Antonio Gomes dept_BR
dc.contributor.authorMoraes, Renata Amaral dept_BR
dc.contributor.authorWinkler, Lisiane de Quadrospt_BR
dc.contributor.authorNeves, Lis Aparecida de Souzapt_BR
dc.contributor.authorSantos, Juliane Cardoso Villelapt_BR
dc.contributor.authorKruppa, Marielept_BR
dc.contributor.authorZucchi, Eliana Miurapt_BR
dc.contributor.authorEscuder, Maria Mercedes Loureiropt_BR
dc.contributor.authorLeal, Andrea Fachelpt_BR
dc.contributor.authorKoyama, Mitti Ayako Harapt_BR
dc.contributor.authorPeres, Maria Fernanda Tourinhopt_BR
dc.contributor.authorCouto, Márcia Therezapt_BR
dc.contributor.authorEluf-Neto, Josept_BR
dc.contributor.authorThe Combine! Research Grouppt_BR
dc.date.accessioned2023-10-11T03:34:42Zpt_BR
dc.date.issued2023pt_BR
dc.identifier.issn1758-2652pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/265802pt_BR
dc.description.abstractIntroduction Pre-exposure prophylaxis (PrEP) delivery based on user needs can enhance PrEP access and impact. We examined whether telehealth for daily oral PrEP delivery could change the indicators of care related to prophylactic use in five Brazilian public HIV clinics (testing centres, outpatient clinics and infectious disease hospitals). Methods Between July 2019 and December 2020, clients on PrEP for at least 6 months could transition to telehealth or stay with in-person follow-up. Clients were clinically monitored until June 2021. A desktop or mobile application was developed, comprising three asynchronous consultations and one annual in-person consultation visit. Predictors influencing telehealth preference and care outcomes were examined. The analysis encompassed intent-to-treat (first choice) and adjustments for sexual practices, schooling, age, duration of PrEP use and PrEP status during the choice period. Results Of 470 users, 52% chose telehealth, with the adjusted odds ratio (aOR) increasing over time for PrEP use (aOR for 25–months of use: 4.90; 95% CI: 1.32–18.25), having discontinued PrEP at the time of the choice (aOR: 2.91; 95% CI: 1.40–6.06) and having health insurance (aOR: 1.91; 95% CI: 1.24–2.94) and decreasing for those who reported higher-risk behaviour (aOR for unprotected anal sex: 0.51; 95% CI: 0.29–0.88). After an average follow-up period of 1.6 years (95% CI: 1.5–1.7), the risk of discontinuing PrEP (not having the medication for more than 90 days) was 34% lower with telehealth (adjusted hazard ratio: 0.66; 95% CI: 0.45–0.97). When adjusted by mixed linear regression, no differences in adherence (measured by mean medication possession rate) were found between in-person and telehealth (p = 0.486) or at pre- and post-telehealth follow-ups (p = 0.245). Sexually transmitted infections increased between the pre-follow-up and post-follow-up choices and were not associated with in-person or telehealth (p = 0.528). No HIV infections were observed. Conclusions Our findings indicate that telehealth for PrEP delivery can enhance service rationalization and reinforce the prevention cascade. This approach reduces prophylaxis interruptions and is mainly preferred by individuals with lower demands for healthcare services.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofJournal of the International AIDS Society. [United States]. Vol. 26, n. 9 (2023), e26173, p. 1-12pt_BR
dc.rightsOpen Accessen
dc.subjectHIVpt_BR
dc.subjectBrazilen
dc.subjectEffectivenessen
dc.subjectPrevenção de doençaspt_BR
dc.subjectProfilaxia pré-exposiçãopt_BR
dc.subjectHuman immunodeficiency virusen
dc.subjectTelemedicinapt_BR
dc.subjectPre-exposure prophylaxisen
dc.subjectPreventionen
dc.subjectBrasilpt_BR
dc.subjectTelehealthen
dc.titleTelehealth effectiveness for pre-exposure prophylaxis delivery in Brazilian public services : the Combine! Studypt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001178114pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples